BACKGROUND: Although guidelines recommend anti-inflammatory therapy for persistent asthma, recent studies suggest that 25% to 35% of patients with asthma may not improve lung function with inhaled corticosteroids. OBJECTIVE: To evaluate potential biomarkers of predicting short-term (6-week) response to inhaled corticosteroid with subsequent evaluation of responders and nonresponders to asthma control over a longer interval (16 additional weeks). METHODS:Eighty-three subjects with asthma off steroid were enrolled in this multicenter study. Biomarkers and asthma characteristics were evaluated as predictors of inhaled corticosteroid response over a 6-week trial for changes in FEV(1) and methacholine PC(20). After this, an additional 4-month trial evaluated asthma control. RESULTS: Although multiple baseline predictors had significant correlations with improvements for short-term inhaled steroid success, the only strong correlations (r >or= +/- 0.6) were albuterol reversibility (r = 0.83; P < .001), FEV(1)/forced vital capacity (r = -0.75; P < .001), and FEV(1) % predicted (r = -0.71; P < .001). Dividing the subjects in the short-term inhaled steroid trial into responders (>5% FEV(1) improvement) and nonresponders (<or=5%) determined the longer-term need for steroids. For the nonresponders, asthma control remained unchanged whether inhaled corticosteroids were continued or were substituted with a placebo (P = .99). The good short-term responders maintained asthma control longer-term only if maintained on inhaled steroids (P = .007). CONCLUSION: The short-term response to inhaled corticosteroids with regard to FEV(1) improvement predicts long-term asthma control. CLINICAL IMPLICATIONS: The decision to use long-term inhaled steroids could be based on a short-term trial. Different therapeutic strategies would need to be established for nonresponders.
RCT Entities:
BACKGROUND: Although guidelines recommend anti-inflammatory therapy for persistent asthma, recent studies suggest that 25% to 35% of patients with asthma may not improve lung function with inhaled corticosteroids. OBJECTIVE: To evaluate potential biomarkers of predicting short-term (6-week) response to inhaled corticosteroid with subsequent evaluation of responders and nonresponders to asthma control over a longer interval (16 additional weeks). METHODS: Eighty-three subjects with asthma off steroid were enrolled in this multicenter study. Biomarkers and asthma characteristics were evaluated as predictors of inhaled corticosteroid response over a 6-week trial for changes in FEV(1) and methacholine PC(20). After this, an additional 4-month trial evaluated asthma control. RESULTS: Although multiple baseline predictors had significant correlations with improvements for short-term inhaled steroid success, the only strong correlations (r >or= +/- 0.6) were albuterol reversibility (r = 0.83; P < .001), FEV(1)/forced vital capacity (r = -0.75; P < .001), and FEV(1) % predicted (r = -0.71; P < .001). Dividing the subjects in the short-term inhaled steroid trial into responders (>5% FEV(1) improvement) and nonresponders (<or=5%) determined the longer-term need for steroids. For the nonresponders, asthma control remained unchanged whether inhaled corticosteroids were continued or were substituted with a placebo (P = .99). The good short-term responders maintained asthma control longer-term only if maintained on inhaled steroids (P = .007). CONCLUSION: The short-term response to inhaled corticosteroids with regard to FEV(1) improvement predicts long-term asthma control. CLINICAL IMPLICATIONS: The decision to use long-term inhaled steroids could be based on a short-term trial. Different therapeutic strategies would need to be established for nonresponders.
Authors: Stanley J Szefler; Richard J Martin; Tonya Sharp King; Homer A Boushey; Reuben M Cherniack; Vernon M Chinchilli; Timothy J Craig; Myrna Dolovich; Jeffrey M Drazen; Joanne K Fagan; John V Fahy; James E Fish; Jean G Ford; Elliot Israel; James Kiley; Monica Kraft; Stephen C Lazarus; Robert F Lemanske; Elizabeth Mauger; Stephen P Peters; Christine A Sorkness Journal: J Allergy Clin Immunol Date: 2002-03 Impact factor: 10.793
Authors: Ruth H Green; Christopher E Brightling; Susan McKenna; Beverley Hargadon; Debbie Parker; Peter Bradding; Andrew J Wardlaw; Ian D Pavord Journal: Lancet Date: 2002-11-30 Impact factor: 79.321
Authors: J M Drazen; E Israel; H A Boushey; V M Chinchilli; J V Fahy; J E Fish; S C Lazarus; R F Lemanske; R J Martin; S P Peters; C Sorkness; S J Szefler Journal: N Engl J Med Date: 1996-09-19 Impact factor: 91.245
Authors: R F Lemanske; C A Sorkness; E A Mauger; S C Lazarus; H A Boushey; J V Fahy; J M Drazen; V M Chinchilli; T Craig; J E Fish; J G Ford; E Israel; M Kraft; R J Martin; S A Nachman; S P Peters; J D Spahn; S J Szefler Journal: JAMA Date: 2001 May 23-30 Impact factor: 56.272
Authors: Eric D Bateman; Homer A Boushey; Jean Bousquet; William W Busse; Tim J H Clark; Romain A Pauwels; Søren E Pedersen Journal: Am J Respir Crit Care Med Date: 2004-07-15 Impact factor: 21.405
Authors: Kelan G Tantisira; Amy Damask; Stanley J Szefler; Brooke Schuemann; Amy Markezich; Jessica Su; Barbara Klanderman; Jody Sylvia; Rongling Wu; Fernando Martinez; Homer A Boushey; Vernon M Chinchilli; Dave Mauger; Scott T Weiss; Elliot Israel Journal: Am J Respir Crit Care Med Date: 2012-04-26 Impact factor: 21.405
Authors: Elena Goleva; Leisa P Jackson; J Kirk Harris; Charles E Robertson; E Rand Sutherland; Clifton F Hall; James T Good; Erwin W Gelfand; Richard J Martin; Donald Y M Leung Journal: Am J Respir Crit Care Med Date: 2013-11-15 Impact factor: 21.405
Authors: Michael E Wechsler; Mario Castro; Erik Lehman; Vernon M Chinchilli; E Rand Sutherland; Loren Denlinger; Stephen C Lazarus; Stephen P Peters; Elliot Israel Journal: Am J Respir Crit Care Med Date: 2011-09-01 Impact factor: 21.405
Authors: T E Albertson; M Schivo; N Gidwani; N J Kenyon; M E Sutter; A L Chan; S Louie Journal: Clin Rev Allergy Immunol Date: 2015-02 Impact factor: 8.667
Authors: Anne M Fitzpatrick; Susan T Stephenson; Milton R Brown; Khristopher Nguyen; Shaneka Douglas; Lou Ann S Brown Journal: J Allergy Clin Immunol Pract Date: 2016-09-21
Authors: Gene T Yocum; Jose F Perez-Zoghbi; Jennifer Danielsson; Aisha S Kuforiji; Yi Zhang; Guanguan Li; M S Rashid Roni; Revathi Kodali; Douglas C Stafford; Leggy A Arnold; James M Cook; Charles W Emala Journal: Am J Physiol Lung Cell Mol Physiol Date: 2018-11-29 Impact factor: 5.464
Authors: Laura E Crotty Alexander; Kathryn Akong-Moore; Stephanie Feldstein; Per Johansson; Anh Nguyen; Elisa K McEachern; Shari Nicatia; Andrew S Cowburn; Joshua Olson; Jae Youn Cho; Hart Isaacs; Randall S Johnson; David H Broide; Victor Nizet Journal: J Mol Med (Berl) Date: 2012-12-19 Impact factor: 4.599